Analysts at Morgan Stanley began coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report issued to clients and investors on Wednesday, Stock Ratings Network.comreports. The firm set an “equal weight” rating and a $320.00 price target on the stock. Morgan Stanley’s price objective suggests a potential upside of 2.61% from the stock’s previous close. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stock opened today at $303.18 and is currently trading at $300.00. The stock showed a negative weekly performance of -3.44%.
Curis, Inc. (NASDAQ:CRIS) which is involved in drug technologies is keeping up with a good fight. However, analysts are still bearish on the stock, but this can only serve as indications that a lot of upside is still available in the stock. Analysts at Roth Capital had little to celebrate in the stock in the recent note to investors discussing CRIS. The analysts trimmed their price target in the stock to $9 from $10. Shares suffered on that note. In the latest reporting, Curis, Inc. (NASDAQ:CRIS) fared nicely with EPS that beat expectation at 5 cents loss against 8 cents loss that Wall Street modeled. However, revenue was a different story, coming in at $1.52 million, below the expected $1.59 million. Curis, Inc. (NASDAQ:CRIS) stock opened at $3.10, in current trading session and currently is at $2.86, by gaining 4.00%.The 52 week range of $2.44-$4.74.Company’s market capitalization is $245.81 million.
EXACT Sciences Corporation (NASDAQ:EXAS) on Mar. 27 announced that the U.S. Food and Drug Administration’s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard, the company’s stool-based DNA (sDNA), non-invasive colorectal cancer screening test. In the company’s 10,000-patient, 90-site DeeP-C pivotal trial—one of the most extensive colorectal cancer screening studies ever conducted in the United States—Exact Sciences’ Cologuard found 92.3% of colorectal cancer in average risk patients based on a combination of DNA and hemoglobin markers. EXACT Sciences Corporation (NASDAQ:EXAS) stock is currently trading at $13.68 .The EPS of the stock is -0.69. Company’s market capitalization is $073.55 million.
Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced that it has received written confirmation from the Food and Drug Administration (FDA) that the clinical hold on the Oxycyte development program has been lifted. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) stock opened the session at $5.96, and now is at $5.58. The 52 week range of the OXBT stock remained $1.19-$11.40 and the day range was $5.48-$5.96.